Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Chapman

Showing results (261-270 of 285) with videos related to

Pageof 29
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)M J Millward, D R Newell, V Mummaneni, et al.
European Journal of Pharmacology|July 25, 2003
In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)Jeffery J Anderson, Margaret J Bradbury, Darlene R Giracello, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancerM J Millward, D R Newell, K Yuen, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 6, 2002
Prediction of respiratory distress syndrome using the Abbott FLM-II amniotic fluid assayLawrence A Kaplan, John F Chapman, Jay L Bock, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|September 19, 2022
Increased spleen volume provoked by temperate head-out-of-water immersionJason M Keeler, Hayden W Hess, Erica Tourula, et al.
Seminars in Oncology|October 1, 1994
Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation studyA H Calvert, M J Lind, S Ghazal-Aswad, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|April 13, 2023
Fluid balance during physical work in the heat is not modified by the menstrual cycle when fluids are freely availableJessica A Freemas, Curtis S Goss, Riley Ables, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonistDehua Huang, Steve F Poon, Deborah F Chapman, et al.
Water Research|November 12, 2013
Assessment of wastewater and recycled water quality: a comparison of lines of evidence from in vitro, in vivo and chemical analysesFrederic D L Leusch, Stuart J Khan, M Monique Gagnon, et al.
Scandinavian Journal of Medicine & Science in Sports|May 16, 2007
Exercise economy does not change after acclimatization to moderate to very high altitudeC Lundby, J A L Calbet, M Sander, et al.
Pageof 29

Showing results (261-270 of 285) with videos related to

Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)M J Millward, D R Newell, V Mummaneni, et al.
European Journal of Pharmacology|July 25, 2003
In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)Jeffery J Anderson, Margaret J Bradbury, Darlene R Giracello, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancerM J Millward, D R Newell, K Yuen, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 6, 2002
Prediction of respiratory distress syndrome using the Abbott FLM-II amniotic fluid assayLawrence A Kaplan, John F Chapman, Jay L Bock, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|September 19, 2022
Increased spleen volume provoked by temperate head-out-of-water immersionJason M Keeler, Hayden W Hess, Erica Tourula, et al.
Seminars in Oncology|October 1, 1994
Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation studyA H Calvert, M J Lind, S Ghazal-Aswad, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|April 13, 2023
Fluid balance during physical work in the heat is not modified by the menstrual cycle when fluids are freely availableJessica A Freemas, Curtis S Goss, Riley Ables, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2004
2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonistDehua Huang, Steve F Poon, Deborah F Chapman, et al.
Water Research|November 12, 2013
Assessment of wastewater and recycled water quality: a comparison of lines of evidence from in vitro, in vivo and chemical analysesFrederic D L Leusch, Stuart J Khan, M Monique Gagnon, et al.
Scandinavian Journal of Medicine & Science in Sports|May 16, 2007
Exercise economy does not change after acclimatization to moderate to very high altitudeC Lundby, J A L Calbet, M Sander, et al.
Pageof 29